The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The evolving role of isatuximab in myeloma: mechanisms, combinations, and future directions
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of isatuximab in multiple myeloma (MM), particularly in combination with other agents and in patients who have previously received daratumumab. Dr Richardson highlights mechanistic differences compared with daratumumab and suggests a potential advantage in select settings, while also noting its expanding use supported by ongoing trials and improved delivery via an on-body infusion device. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
